Hairy Cell Leukemia is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hairy Cell Leukemia have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hairy Cell Leukemia compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hairy Cell Leukemia overview
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness, and weight loss. Risk factors include exposure to radiation, chemicals, and saw dust. Treatment includes surgery, chemotherapy, and radiation therapy.
For a complete picture of PTSR and LoA scores for drugs in Hairy Cell Leukemia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.